We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 20, 2020

Toxicities, Body Composition, and hrQoL Among Long-Term Survivors Treated With Antibodies to PD-1 and PD-L1

European Journal of Cancer


Additional Info

European Journal of Cancer
Survivorship in Immune Therapy: Assessing Toxicities, Body Composition and Health-Related Quality of Life Among Long-Term Survivors Treated With Antibodies to Programmed Death-1 Receptor and Its Ligand
Eur. J. Cancer 2020 Jun 26;135(xx)211-220, JR Patrinely, AC Young, H Quach, GR Williams, F Ye, R Fan, L Horn, KE Beckermann, EA Gillaspie, JA Sosman, DL Friedman, JJ Moslehi, DB Johnson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading